A PHASE I STUDY OF CLOFARABINE PLUS HIGH DOSE MELPHALAN AS A CONDITIONING REGIMEN FOR ALLOGENEIC TRANSPLANTATION

被引：0

作者：

Kirschbaum, M. H. ^{[1
]}

Stein, A. S. ^{[1
]}

Nakamura, R. ^{[1
]}

Auayporn, N. ^{[1
]}

Popplewell, L. ^{[1
]}

Delioukina, M. ^{[1
]}

Chen, R. ^{[1
]}

Snyder, D. ^{[1
]}

Conrad, J. ^{[1
]}

Frankel, P. ^{[1
]}

Forman, S. J. ^{[1
]}

机构：

[1] City Hope Natl Med Ctr, Duarte, CA 91010 USA

来源：

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2010年 / 16卷 / 02期

关键词：

D O I：

10.1016/j.bbmt.2009.12.367

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

323

引用

页码：S278 / S278

页数：1

共 50 条

[21] Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long Term Study Results [J].

Kebriaei, Partow ;

Bassett, Roland ;

Lyons, Genevieve ;

Valdez, Ben ;

Ledesma, Celina ;

Rondon, Gabriela ;

Oran, Betul ;

Ciurea, Stefan ;

Alousi, Amin ;

Popat, Uday ;

Patel, Krina ;

Ahmed, Sairah ;

Olson, Amanda ;

Bashir, Qaiser ;

Shah, Nina ;

Jones, Roy ;

Marin, David ;

Rezvani, Katayoun ;

Nieto, Yago ;

Khouri, Issa ;

Qazilbash, Muzaffar ;

Hosing, Chitra ;

Shpall, Elizabeth ;

Champlin, Richard E. ;

Andersson, Borje S. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (02) :285-292

[22] Clofarabine and Total Body Irradiation as a Conditioning Regimen for Allogeneic Stem Cell Transplantation in High-Risk Acute Leukemia [J].

Atoui, Ali ;

Dulery, Remy ;

Terro, Khodr ;

Abou Dalle, Iman ;

Bazarbachi, Ali ;

Mohty, Mohamad ;

El Cheikh, Jean .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 :S432-S432

[23] A phase I/II study of escalating doses of thalidomide in conjunction with bortezomib and high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma [J].

Biran, Noa ;

Rowley, Scott D. ;

Vesole, David H. ;

Zhang, Shijia ;

Donato, Michele L. ;

Skarbnik, Alan P. ;

Richter, Joshua ;

Pecora, Andrew ;

Siegel, David S. .

BONE MARROW TRANSPLANTATION, 2019, 54 (11) :1881-1891

[24] A phase I/II study of escalating doses of thalidomide in conjunction with bortezomib and high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma [J].

Noa Biran ;

Scott D. Rowley ;

David H. Vesole ;

Shijia Zhang ;

Michele L. Donato ;

Alan P. Skarbnik ;

Joshua Richter ;

Andrew Pecora ;

David S. Siegel .

Bone Marrow Transplantation, 2019, 54 :1881-1891

[25] Fludarabine/full dose i.v. busulfan conditioning regimen in allogeneic PBSC transplantation for high risk patients [J].

Chunduri, S. ;

Dobogai, L. C. ;

Peace, D. ;

Saunthararajah, Y. ;

Quigley, J. ;

Chen, Y. -H. ;

Boccuni, P. ;

Hoffman, R. ;

Mahmud, N. ;

Beri, R. ;

Hurter, E. ;

Rondelli, D. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (02) :84-84

[26] Phase I Trial of High-Dose Clofarabine and Busulfan as a Myeloablative Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Leukemia [J].

Farag, Sherif ;

Wood, Lisa L. ;

Schwartz, Jennifer E. ;

Srivastava, Shivani ;

Nelson, Robert P., Jr. ;

Robertson, Michael ;

Abonour, Rafat ;

Sayar, Hamid ;

Cripe, Larry D. .

BLOOD, 2009, 114 (22) :86-86

[27] Bortezomib after high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with multiple myeloma: A comparison with the historical conditioning regimen with melphalan alone [J].

Ferini, G. A. ;

Arbelbide, J. A. ;

Basquiera, A. L. ;

Nucifora, E. ;

Schutz, N. ;

Otero, V. ;

Fantl, D. .

BONE MARROW TRANSPLANTATION, 2017, 52 :S461-S462

[28] Busulfan and melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma [J].

Jung, Sung-Hoon ;

Lee, Je-Jung ;

Kim, Jin Seok ;

Min, Chang-Ki ;

Kim, Kihyun ;

Choi, Yunsuk ;

Eom, Hyeon-Seok ;

Joo, Young Don ;

Kim, Sung-Hyun ;

Kwak, Jae-Yong ;

Kang, Hye Jin ;

Lee, Jae Hoon ;

Lee, Ho Sup ;

Mun, Yeung-Chul ;

Moon, Joon Ho ;

Sohn, Sang Kyun ;

Park, Seong Kyu ;

Park, Yong ;

Shin, Ho-Jin ;

Yoon, Sung-Soo .

BONE MARROW TRANSPLANTATION, 2018, 53 :262-263

[29] High dose idarubicine, busulphan and melphalan conditioning regimen for lymphoproliferative disorders [J].

Trasarti, S ;

Meloni, G ;

Capria, S ;

Bongarzoni, V ;

Ferrazza, G ;

Iodice, F ;

Proia, A ;

Trisolini, SM ;

Mandelli, F .

BONE MARROW TRANSPLANTATION, 1998, 21 :S100-S100

[30] High dose Melphalan/Thiotepa conditioning regimen for resistant lymphoma. [J].

Kirschbaum, MH ;

Gur, O ;

Nadav, L ;

Naparstek, E .

BLOOD, 2002, 100 (11) :477B-477B

← 1 2 3 4 5 →